Comparative Pharmacology
Head-to-head clinical analysis: NATURAL ESTROGENIC SUBSTANCE ESTRONE versus PREMPHASE PREMARIN CYCRIN 14 14.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NATURAL ESTROGENIC SUBSTANCE ESTRONE versus PREMPHASE PREMARIN CYCRIN 14 14.
NATURAL ESTROGENIC SUBSTANCE-ESTRONE vs PREMPHASE (PREMARIN;CYCRIN 14/14)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrone binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent estrogenic effects on target tissues.
PREMPHASE combines conjugated estrogens (PREMARIN) and medroxyprogesterone acetate (CYCRIN). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which regulate gene transcription and produce effects in tissues such as the endometrium, breast, and bone. Medroxyprogesterone acetate is a progestin that induces secretory changes in the endometrium and reduces the risk of endometrial hyperplasia associated with estrogen therapy.
0.1 to 0.5 mg intramuscularly 2 to 3 times per week for estrogen replacement therapy
One tablet daily (conjugated estrogens 0.625 mg/medroxyprogesterone acetate 5 mg) for 14 days, followed by one tablet daily (conjugated estrogens 0.625 mg) for 14 days; continuous cycling. Oral administration.
None Documented
None Documented
Terminal half-life: 24-48 hours (prolonged due to enterohepatic recirculation and tissue distribution).
Conjugated estrogens: terminal half-life 10–24 h (accumulation with daily dosing). MPA: terminal half-life 12–33 h (mean ∼17 h).
Renal: ~50% (as glucuronide and sulfate conjugates), Biliary/Fecal: ~50% (enterohepatic recirculation).
Conjugated estrogens and MPA are primarily excreted in urine (∼90% as glucuronide and sulfate conjugates) and feces (∼10% as unabsorbed drug and biliary metabolites).
Category C
Category C
Estrogen
Estrogen/Progestin Combination